Daily Archives: February 24, 2017
Fri, Feb 24 – Top 10 Medical News Stories
24 Feb, 2017 | 00:01h | UTC
1 – Diabetic Retinopathy: A Position Statement by the American Diabetes Association
Source: Medscape – First ADA Guidance on Diabetic Retinopathy in 15 Years (free registration required)
2 – When Evidence Says No, But Doctors Say Yes: Years after research contradicts common practices, patients continue to demand them and doctors continue to deliver. The result is an epidemic of unnecessary and unhelpful treatment – ProPublica (RT @HenrikVogt and @MaryanneDemasi)
This very interesting commentary went “viral” in the medical community.
“The essence of medical professionalism is not to say “yes” but to say “no”” (RT @HenrikVogt)
Cesarean sections (CS) are more likely to be performed by for-profit hospitals as compared with non-profit hospitals. The researchers recommend examination of incentive structures of for-profit hospitals including reimbursement policies to decrease unnecessary CS and promote strategies that encourage best clinical judgement and outcome
6 – Bad Hospital Design Is Making Us Sicker – The New York Times (RT @KentBottles)
7 – Cancer Prevention Overview – PDQ Cancer Information Summaries: National Cancer Institute (US)
Source: EvidenceAlerts (free resource to find articles of interest in all specialties – registration required)
Antiplatelet agents prevent spontaneous preterm birth in pregnant women at risk for preeclampsia
9 – Implanted Cardiac Devices Pass an MRI Test – Physician’s First Watch
See also: MRI May Be Safe with Many Non-MRI-Conditional Heart Devices – MedPage Today
Original Article Abstract ($ required for full text): Assessing the Risks Associated with MRI in Patients with a Pacemaker or Defibrillator – New England Journal of Medicine
Nonthoracic MRI was safe if used with strict protocol
10 – Liraglutide Associated with Less Progression in Prediabetes – Physician’s First Watch
Original Article Abstract ($ required for full text): 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial – The Lancet
Interesting, but they could have tested Liraglutide against Metformin, the drug usually used for this purpose